2076975 2077203
최종편집 2024-03-29 17:03 (금)
SGLT-2i/DPP-4i combination therapy receives insurance coverage in Korea
상태바
SGLT-2i/DPP-4i combination therapy receives insurance coverage in Korea
  • Jaehoon SongㆍHyeokgi Lee, Newsmp
  • 승인 2023.04.27 15:05
  • 댓글 0
이 기사를 공유합니다

CosentyxㆍDupixent 300mg added, ForxigaㆍXigduo upper limit lowered

[Newsmp] With the application of health insurance to the combined therapy of SGLT-2 inhibitors and DDP-4 inhibitors, combination drugs that were not previously covered by insurance after their release have all become eligible for coverage.

The Ministry of Health and Welfare revised and issued a revision of the ‘Pharmaceutical benefit list and the table of the upper limit of benefits’ on Tuesday.

According to the announcement, next month, combination drugs of SGLT-2 inhibitors and DDP-4 inhibitors, including Stegluzan (MSD) and Esglito (Boehringer Ingelheim), Zemidapa (LG Chem), and Qtern (AstraZeneca), will all be added to the benefits list simultaneously.

Stegluzan consists of ertugliflozin (brand name: Steglatro) and sitagliptin (brand name: Januvia); Esglito comprises empagliflozin (brand name: Jardiance) and linagliptin (brand name: Tradjenta); Zemidapa is a combination of dapagliflozin (brand name: Farxiga) and gemigliptin (brand name: Zemiglo); and Qtern contains dapagliflozin and saxagliptin (brand name: Onglyza).

Stegluzan 5/100mg will cost KRW 846 per tablet, Esglito will cost KRW 755 per tablet for 10/5mg and KRW 858 per tablet for 25/5mg, Zemidapa will cost KRW 940 per tablet, and Qtern 5/10mg will cost KRW 833 per tablet.

Beigene's blood cancer treatment drug, Brukinsa, has been added to the benefits list. The upper limit has been set at KRW 34,100 per 80mg capsule.

Dupixent (Sanofi) and Cosentyx Unoready Pen (Novartis), two auto-immune disease therapies, which are interleukin inhibitors, will be added to the list with an additional 300mg formulation.

Invega's lineup by Janssen will now include two additional dosages of Invega Hafyera injection. The upper limit for a 3.5ml vial is set at KRW 1,442,208 and KRW 1,777,640 for a 5ml vial.

The supplier’s name for Ultomiris will be changed from Handok to AstraZeneca.

Among the existing products, Hemlibra (JW Pharmaceutical), a treatment for hemophilia, will have its price ceiling for the five dosages reduced by 5.0% each.

Merck's Maven Clad will see a decrease of 6.9%, and Concor's 2.5mg and 5mg dosages will be reduced by 9.1% and 9.9%. Furthermore, Boryung Pharmaceutical's Kanarb will experience a 1.7% reduction for the 120mg and 60mg dosages and a 1.8% reduction for the 30mg dosage.

Eisatine by Alvogen Korea will be reduced by 12.0%, and Blincyto by Amgen will be decreased by 1.8%. In addition, both 2.5mg and 5mg dosages of Eliquis by BMS will see a 3.5% reduction.

Due to patent expiration, AstraZeneca Korea's Xigduo XR Tab. will see a decrease of 30.4% for the 10/1000mg dosage and 35.7% for the 10/500mg dosage. Forxiga will be reduced by 30.0%, and an additional 23.5% reduction will be implemented on April 8th, 2024.

The price of Orfadin supplied by Korea Orphan & Essential Drug Center will be reduced by 40.0% from 37,386 won to 22,420 won per capsule.

On the other hand, Myung In Pharmaceutical's Myungin Bromazepam Tab. 3mg will undergo a 51.5% increase in the price ceiling, rising from KRW 33 to KRW 50 per capsule.

SamChunDang Pharm's Casfun (two doses of 50/70mg) that was scheduled for a 10% reduction on the 1st of next month will maintain the current upper limit and be reduced according to the previously planned limit from May 1 of next year. Similarly, MSD's Cancidas (two doses of 50/70mg), which was planned for a reduction of 21.6% and 22.3%, will also maintain its current limit and experience the previously scheduled reduction next year.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.